Tengion Inc TNGNQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.02
- Market Cap
- $40.25
- Volume/Avg
- 1,570 / 502
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 27
- Website
- —
Valuation
|
Metric
|
TNGNQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
TNGNQ
Financial Strength
|
Metric
|
TNGNQ
|
|---|---|
Quick Ratio | 0.10 |
Current Ratio | 0.10 |
Interest Coverage | −7.24 |
Quick Ratio
TNGNQ
Profitability
|
Metric
|
TNGNQ
|
|---|---|
Return on Assets (Normalized) | −125.62% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
TNGNQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hvzqkhnzh | Vgch | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lwwyqjv | Shxvs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fljlvlss | Tzwyhh | $97.8 Bil | |
MRNA
| Moderna Inc | Ybqdyqfh | Vzld | $38.8 Bil | |
ARGX
| argenx SE ADR | Lnqtcnb | Dplh | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zxbskgp | Nqd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gjcdvjxdv | Kyzvwvm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jyjhmlhz | Qdylbcg | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ftfwqpmn | Djpfvky | $12.5 Bil | |
INCY
| Incyte Corp | Djgwvlpvb | Cpfnhg | $11.5 Bil |